Osseointegrated Exoskeleton ExoBone Enters Clinical Trials: Prosthetics No Longer Sleeve Over Skin but Connect Directly to Bone

In January 2029, Chalmers University of Technology in Sweden announced that the osseointegrated exoskeleton system ExoBone entered multi-center clinical trials. ExoBone surgically implants a titanium alloy fixture at the end of the amputee patient's residual bone, with the exoskeleton's mechanical actuator connecting directly to this implant, bypassing traditional socket-type connections.

Traditional prosthetics wrap around the residual limb via sockets, with force transfer requiring passage through soft tissue, achieving only 30-40% efficiency compared to natural limbs. ExoBone's osseointegrated connection transfers force directly to bone, achieving 85% efficiency. More importantly, the bone implant integrates neural electrodes that capture residual nerve signals to control exoskeleton movement.

The clinical trial's first 12 subjects were all below-knee amputees. After 3 months of adaptive training, subjects scored significantly better than traditional prosthetic users in walking speed, stair-climbing ability, and terrain adaptability. Eight subjects reported that while using ExoBone, they almost forgot they were amputees — a "prosthetic fusion sensation" difficult to achieve with traditional prosthetics.

ExoBone's surgery costs approximately 30,000 euros, with exoskeleton hardware costing approximately 50,000 euros. Chalmers University is negotiating technology licensing with multiple prosthetic manufacturers.